局部晚期子宫内膜癌术前化疗及手术后加用术后放疗与结局改善相关
该研究基于美国国家癌症数据库2010至2016年FIGO III/IV期局部晚期子宫内膜癌接受确定性手术并化疗的13369例病例,比较术前化疗(PreCT,1059例)与术后化疗(PostCT,12310例)队列。PreCT总生存低于PostCT,但PreCT术后加用放疗与生存改善相关(5年OS 20.5% vs 50%)。
要点
- PreCT队列总生存低于PostCT(多因素HR 1.873,P < .001)。
- PreCT术后加用放疗与生存改善相关(5年OS 20.5% vs 50%;多因素HR 0.337,P < .001)。
- PreCT切缘阴性率低于PostCT(72% vs 84%,P < .001),约19%病理T分期下降、11% N分期下降。
核心结论
- 术前化疗用于肿瘤学预后因素更差、许多初始可能不可切除的病例,尽管与肿瘤降期相关,但生存低于直接手术,可能源于这些基线差异。
- 术前化疗后手术加用术后放疗与生存改善相关。
研究设计与样本
- 美国国家癌症数据库回顾性查询2010至2016年FIGO III/IV期局部晚期子宫内膜癌接受确定性手术并化疗的病例,排除接受术前放疗者,纳入接受术后放疗者。
- 共识别13369例,分为术前化疗伴或不伴术后化疗队列(PreCT,1059例)和术后化疗队列(PostCT,12310例)用于切缘评估参考。
- 主要终点为总生存、手术切缘状态、降期率以及PreCT队列中辅助放疗对总生存的影响,采用单变量和多变量Cox回归分析。
主要发现
- PreCT总生存低于PostCT(单变量HR 2.18,P < .001;多变量HR 1.873,P < .001)。
- PreCT切缘阴性者总生存仍差于PostCT切缘阴性者(单变量HR 2.20,P < .001;多变量HR 1.84,P < .001),但PreCT切缘阴性者生存与PostCT切缘阳性者相似(单变量HR 0.825,P < .001;多变量P = .885)。
- PreCT队列术后加用放疗与生存改善相关(5年OS 20.5% vs 50%;单变量HR 0.450,P < .001;多变量HR 0.337,P < .001)。
- PreCT切缘阴性率低于PostCT(72% vs 84%,P < .001);PreCT中约19%病例病理T分期低于临床T分期,11%病例N分期下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to examine outcomes of patients with locally advanced endometrial cancer who undergo neoadjuvant chemotherapy followed by surgery (PreCT) with/without postoperative adjuvant radiation therapy. A secondary analysis of down staging and margin clearance was made with reference to those receiving upfront surgery and then adjuvant chemotherapy (PostCT). METHODS AND MATERIALS: The National Cancer Database was queried for FIGO (The International Federation of Gynecology and Obstetrics) stage III/IV locally advanced endometrial cancer cases who underwent definitive surgery from 2010 to 2016 and received chemotherapy as part of their treatment. Cases were classified into 2 cohorts: preoperative chemotherapy +/- postoperative chemotherapy cohort (PreCT) and postoperative chemotherapy cohort (PostCT) for reference for margin assessment. Cases who received preoperative radiation therapy were excluded while those who received postoperative radiation were included in the analysis. Primary endpoints were overall survival (OS), surgical margin status, rate of downstaging, and effect of adjuvant radiation therapy on OS among the PreCT cohort. Univariable (UVA) and multivariable (MVA) Cox regression analyses were performed. RESULTS: A total of 13,369 cases were identified with 1059 in PreCT and 12,310 in PostCT cohorts. PreCT had lower OS than PostCT (UVA: hazard ratio [HR], 2.18; P < .001; MVA: HR, 1.873; P < .001). PreCT cases with negative margins, who presumably had unresectable tumors initially, also had worse OS compared with PostCT with negative margins (UVA: HR, 2.20; P < .001; MVA: HR, 1.84; P < .001); however, PreCT with negative margins had similar survival to PostCT with positive margins (UVA: HR, 0.825; P < .001; MVA: P = .885). The addition of radiation after surgery in the PreCT cohort was associated with improved survival (5-year OS 20.5% compared with 50%, respectively; UVA: HR, 0.450; P < .001; MVA: HR, 0.337; P < .001). Although fewer cases in PreCT had negative margins compared with PostCT (72% compared with 84%, P < .001), approximately 19% of cases in PreCT had lower pathologic T-stage compared with clinical T-stage and 11% had lower N-stage. CONCLUSIONS: Neoadjuvant chemotherapy was given in cases with worse oncologic prognostic factors, many of whom were likely unresectable at outset, compared with those who received postoperative chemotherapy. Although neoadjuvant chemotherapy is associated with tumor downstaging, survival is lower than with primary surgery probably because of these baseline differences. The addition of adjuvant radiation after surgery in cases who received preoperative chemotherapy is associated with improved survival.
引用
- Salamekh S, Yan J, D'Cunha P, et al. Addition of Postoperative Radiation Therapy After Preoperative Chemotherapy and Surgery in Patients With Locally Advanced Endometrial Cancer Is Associated With Improved Outcomes. Adv Radiat Oncol. 2022. PMID: 36711063. doi:10.1016/j.adro.2022.101126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。